CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Clinical trial NCT07328503 · RECRUITING
Trial details
- NCT number
- NCT07328503
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-16
- Primary completion
- 2030-01-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.